Aldeyra Therapeutics, Inc. (ALDX) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 18 Buy, 1 Hold.
The consensus price target is $7.00, representing an upside of 291.1% from the current price $1.79.
Analysts estimate Earnings Per Share (EPS) of $-0.93 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.94 vs est $-0.93 (missed -1%). 2025: actual $-0.56 vs est $-0.56 (beat +0.4%). Analyst accuracy: 99%.
ALDX Stock — 12-Month Price Forecast
$7.00
▲ +291.06% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Aldeyra Therapeutics, Inc., the price target is $7.00.
The average price target represents a +291.06% change from the last price of $1.79.
ALDX Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Aldeyra Therapeutics, Inc. in the past 3 months
EPS Estimates — ALDX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.94
vs Est –$0.93
▼ 1.0% off
2025
Actual –$0.56
vs Est –$0.56
▲ 0.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ALDX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
